- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07521007
Faza 2b badania klinicznego preparatu YN001 u dorosłych z miażdżycą tętnic wieńcowych (PURIFY-TIMI 81)
Randomizowane, wieloośrodkowe, podwójnie ślepe, równoległe, kontrolowane placebo badanie kliniczne fazy 2b mające na celu ocenę skuteczności i bezpieczeństwa preparatu YN001 u dorosłych z miażdżycą tętnic wieńcowych
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.
A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Jingmei Zhang, Master
- Numer telefonu: 0086 010 82599080
- E-mail: zhangjingmei@innovmedicine.com
Kopia zapasowa kontaktu do badania
- Nazwa: Kaiqi Zong, Master
- Numer telefonu: 0086 010 82599080
- E-mail: zongkaiqi@innovmedicine.com
Lokalizacje studiów
-
-
New South Wales
-
Penrith, New South Wales, Australia, 2750
- Rekrutacyjny
- Cannopy Clinical Research
-
Kontakt:
- Karen Kaluhin, MD
- Numer telefonu: 0061 0491 276 512
- E-mail: kkaluhin@canopycr.com.au
-
-
Queensland
-
Brisbane, Queensland, Australia, 4064
- Rekrutacyjny
- Core Research Group Pty Ltd.
-
Kontakt:
- David Colquhou, MD
- Numer telefonu: 614-1184-2788
- E-mail: d.colquhoun@uq.edu.au
-
-
Victoria
-
Altona N., Victoria, Australia, 3025
- Rekrutacyjny
- Canopy Clinical Research
-
Kontakt:
- Oscar Walsh, MD
- Numer telefonu: 0061 03 9968 7601
- E-mail: owalsh@canopycr.com.au
-
-
-
-
An
-
Hefei, An, Chiny, 230022
- Rekrutacyjny
- The First Affiliated Hospital of Anhui Medical Unversity
-
Kontakt:
- Jianlong Wang, MD
- Numer telefonu: 0086-13681292304
- E-mail: Wjlmll@sina.com
-
-
Anhui
-
Hefei, Anhui, Chiny, 230001
- Rekrutacyjny
- Anhui Provincial Hospital
-
Kontakt:
- Kangyu Chen, MD
- Numer telefonu: 0086 18056005099
- E-mail: ustccky@126.com
-
Główny śledczy:
- Kangyu Chen, MD
-
Pod-śledczy:
- Chao Gao, MD
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chiny, 100035
- Rekrutacyjny
- Beijing Jishuitan Hospital
-
Główny śledczy:
- Wei Liu, MD
-
Kontakt:
- Qingwei Ji, MD
- Numer telefonu: 0086 18376642655
- E-mail: jqwl24@163.cou
-
Główny śledczy:
- Qingwei Ji, MD
-
Beijing, Beijing Municipality, Chiny, 100029
- Rekrutacyjny
- Anzhen Hospital
-
Kontakt:
- Yuyang Liu, MD
- Numer telefonu: 0086 010-64456488
- E-mail: liuyy803803@163.com
-
Główny śledczy:
- Yuyang Liu, MD
-
Beijing, Beijing Municipality, Chiny, 101100
- Jeszcze nie rekrutacja
- Beijing Luhe Hospital
-
Kontakt:
- Guangyao Zhai, MD
- Numer telefonu: +86 1069543901
- E-mail: drzhaiguangyao@163.com
-
-
Fujian
-
Fuzhou, Fujian, Chiny, 350001
- Rekrutacyjny
- Fujian Medical University Union Hospital
-
Kontakt:
- Mingfang Ye, MD
- Numer telefonu: 0086 13960818759
- E-mail: xieheyemingfang@163.com
-
Główny śledczy:
- Mingfang Ye, MD
-
Pod-śledczy:
- Zhaoyang Chen, MD
-
-
Gansu
-
Lanzhou, Gansu, Chiny, 730030
- Rekrutacyjny
- The Second Hospital & Clinical Medical School Lanzhou University
-
Kontakt:
- Feng Bai, MD
- Numer telefonu: 0086-13609363049
- E-mail: baifeng@medmail.com.cn
-
-
Guangdong
-
Guangzhou, Guangdong, Chiny, 510080
- Rekrutacyjny
- Guangdong Provincial People's Hospital
-
Kontakt:
- Ning Tan, MD
- E-mail: tanning100@126.com
-
Kontakt:
- Numer telefonu: 0086-13903073651
- E-mail: tangning100@126.com
-
-
Heilongjiang
-
Daqing, Heilongjiang, Chiny, 163316
- Rekrutacyjny
- Daqing People's Hospital
-
Kontakt:
- Shu Zhang
- Numer telefonu: +86-459-6612898
- E-mail: dqsrmyygcp@163.com
-
Harbin, Heilongjiang, Chiny, 150001
- Rekrutacyjny
- The First Affiliated Hospital of Harbin Medical University
-
Kontakt:
- Lu Fu, MD
- Numer telefonu: 0086 137 9668 4968
- E-mail: fuluyidayi@163.com
-
Główny śledczy:
- Lu Fu, MD
-
Główny śledczy:
- Yongtai Gong, MD
-
-
Hubei
-
Wuhan, Hubei, Chiny, 430071
- Rekrutacyjny
- Zhongnan Hospital of Wuhan University
-
Kontakt:
- Xiaorong Hu, MD
- Numer telefonu: 0086 15927681634
- E-mail: huzrzn@whu.edu.cn
-
Główny śledczy:
- Xiaorong Hu, MD
-
-
Hunan
-
Changsha, Hunan, Chiny, 410008
- Rekrutacyjny
- The Second Xiangya Hospital fo Central South University
-
Kontakt:
- Xinqun Hu, MD
- Numer telefonu: 0086-13307313627
- E-mail: huxinqungs@163.com
-
-
Jilin
-
Changchun, Jilin, Chiny, 130033
- Rekrutacyjny
- The First Hospital of Jilin University
-
Główny śledczy:
- Qian Tong, MD
-
Kontakt:
- Qian Tong, MD
- Numer telefonu: 0086 13074337289
- E-mail: tongqian187@aliyun.com
-
-
Liaoning
-
Shenyang, Liaoning, Chiny, 110015
- Rekrutacyjny
- The People's Hospital of Liaoning Province
-
Główny śledczy:
- Ying Liu, MD
-
Kontakt:
- Ying Liu, MD
- Numer telefonu: 0086 13840065379
- E-mail: liuyingwangli@126.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Chiny, 710068
- Rekrutacyjny
- Shaanxi Provincial People's Hospital
-
Kontakt:
- Xiling Shou, MD
- Numer telefonu: 0086 18966700335
- E-mail: shouxiling@163.com
-
-
Shandong
-
Jinan, Shandong, Chiny
- Rekrutacyjny
- Central Hospital Affiliated to Shandong First Medicial University
-
Kontakt:
- Guohai Su, MD
- Numer telefonu: 0086 19953193319
- E-mail: gttstg@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 200032
- Rekrutacyjny
- Fudan University-Zhongshan Hospital
-
Główny śledczy:
- Junbo Ge, MD
-
Kontakt:
- Junbo Ge, MD
- Numer telefonu: 021-64041990
- E-mail: ge.junbo@zs-hospital.sh.cn
-
Pod-śledczy:
- Yuxiang Dai, MD
-
Shanghai, Shanghai Municipality, Chiny, 200001
- Rekrutacyjny
- Renji Hospital Shanghai Jiaotong University school of medicine
-
Kontakt:
- Jun Bu, MD
- Numer telefonu: 0086 13601958108
- E-mail: pujun310@hotmail.com
-
Główny śledczy:
- Jun Bu, MD
-
-
Sichuan
-
Chengdu, Sichuan, Chiny, 610041
- Rekrutacyjny
- West China Hospital of Sichuan University
-
Kontakt:
- Yong He, MD
- Numer telefonu: 0086 18980602038
- E-mail: zznnyeah@163.com
-
Główny śledczy:
- Yong He, MD
-
Chengdu, Sichuan, Chiny, 610072
- Rekrutacyjny
- Sichuan Provincial People's Hospital
-
Kontakt:
- Jianhong Tao, DM
- Numer telefonu: 86-189 8183 8875
- E-mail: Taojianhong06@medmail.com.cn
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chiny, 300211
- Rekrutacyjny
- The Second Hospital of Tianjin Medical University
-
Kontakt:
- Tong Liu, MD
- Numer telefonu: 0086 13902183163
- E-mail: liutongdoc@126.com
-
Główny śledczy:
- Tong Liu, MD
-
Tianjin, Tianjin Municipality, Chiny, 300121
- Rekrutacyjny
- Tianjin People's Hospital
-
Główny śledczy:
- Zhuhua Yao, MD
-
Kontakt:
- Zhuhua Yao, MD
- Numer telefonu: 0086 13902199877
- E-mail: tjyzhpci@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chiny, 310006
- Rekrutacyjny
- Zhejiang Provincial People's Hospital
-
Kontakt:
- Lihong Wang, MD
- Numer telefonu: 0086-13666690598
- E-mail: wlhhz@hotmail.com
-
Suzhou, Zhejiang, Chiny, 215006
- Rekrutacyjny
- The First Affiliated Hospital of Soochow University
-
Kontakt:
- Tingbo Jiang, MD
- Numer telefonu: 0086-18906201122
- E-mail: jiangtingbo6797@163.com
-
Wenzhou, Zhejiang, Chiny, 325000
- Rekrutacyjny
- The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
-
Kontakt:
- lianpin Wu, MD
- E-mail: 198019@wzhealth.com
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R2H 2A6
- Jeszcze nie rekrutacja
- St. Boniface Hospital
-
Kontakt:
- Shuangbo Liu
- Numer telefonu: 204-237-2793
- E-mail: sliu@sbgh.mb.ca
-
-
Ontario
-
London, Ontario, Kanada, N5A 5A5
- Jeszcze nie rekrutacja
- London Health Sciences Centre
-
Kontakt:
- Habib Khan
- Numer telefonu: 519-663-3197
- E-mail: habib.khan@lhsc.on.ca
-
North York, Ontario, Kanada, M6B 3H7
- Jeszcze nie rekrutacja
- North York Diagnostic and Cardiac Centre
-
Kontakt:
- Subodh Verma, MD
- Numer telefonu: 416-436-0244
- E-mail: subodh.verma@unityhealth.to
-
Toronto, Ontario, Kanada, M5B 1W8
- Jeszcze nie rekrutacja
- St. Michael's Hospital
-
Kontakt:
- John Graham
- Numer telefonu: 416-864-6060
- E-mail: John.Graham@unityhealth.to
-
Vaughan, Ontario, Kanada, L6A 4N9
- Jeszcze nie rekrutacja
- Cardiac Clinic
-
Kontakt:
- Navneet Singh
- Numer telefonu: 905-417-3001
- E-mail: navneet.singh@thp.ca
-
-
Toronto
-
Toronto, Toronto, Kanada, M5G 2N2
- Jeszcze nie rekrutacja
- Toronto General Hospital - University Health Network
-
Kontakt:
- Jacob Udell
- Numer telefonu: 416-340-4800
- E-mail: jay.udell@utoronto.ca
-
-
-
-
Alabama
-
Huntsville, Alabama, Stany Zjednoczone, 35801-4312
- Rekrutacyjny
- Heart Center Research, LLC
-
Kontakt:
- Walter Haught, MD
- Numer telefonu: 256-519-8472
- E-mail: hhaught@theheartcenter.md
-
-
California
-
Covina, California, Stany Zjednoczone, 91740
- Jeszcze nie rekrutacja
- Thrive Clinical Research Group, LLC
-
Kontakt:
- Sami Hayek
- Numer telefonu: 818-280-4220
- E-mail: samihayek82@hotmail.com
-
Kontakt:
- E-mail: shayek@foothillcardiology.com
-
Lincoln, California, Stany Zjednoczone, 95648
- Jeszcze nie rekrutacja
- Clinical Trials Research
-
Kontakt:
- Jeffrey Wayne, MD
- Numer telefonu: 916-434-8230
- E-mail: jwaynemd@ctrsites.com
-
Los Alamitos, California, Stany Zjednoczone, 90720
- Jeszcze nie rekrutacja
- University of California Irvine Medical Center - Cardiovascular Center
-
Kontakt:
- Arnold Seto
- Numer telefonu: 562-598-3200
- E-mail: arnold.seto@va.gov
-
Stanford, California, Stany Zjednoczone, 94305-2200
- Jeszcze nie rekrutacja
- Stanford Health Care General Cardiology
-
Kontakt:
- Fahim Abbasi, MD
- Numer telefonu: 650-723-6459
- E-mail: fahim@stanford.edu
-
Torrance, California, Stany Zjednoczone, 90502-2006
- Rekrutacyjny
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Kontakt:
- Matthew Budoff, MD
- Numer telefonu: 310-222-3641
- E-mail: mbudoff@lundquist.org
-
-
Florida
-
Boca Raton, Florida, Stany Zjednoczone, 33434
- Jeszcze nie rekrutacja
- Flourish Research - Boca Raton
-
Kontakt:
- Richard Goldman
- Numer telefonu: 561-756-8206
- E-mail: rgoldman@flourishresearch.com
-
Hialeah, Florida, Stany Zjednoczone, 33016-1895
- Rekrutacyjny
- New Generation of Medical Research, LLC.
-
Kontakt:
- Karelia Ruiz
- Numer telefonu: 305-828-9100
- E-mail: kareliar@ngmresearch.com
-
St. Petersburg, Florida, Stany Zjednoczone, 33709
- Rekrutacyjny
- HCA Florida Heart Institute
-
Kontakt:
- Robert Sanchez, MD
- Numer telefonu: 727-490-2100
- E-mail: robert.sanchez7@hcahealthcare.com
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30303-3049
- Jeszcze nie rekrutacja
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park
-
Kontakt:
- Modele Ogunniyi
- Numer telefonu: 404-616-4440
- E-mail: modele.ogunniyi@emory.edu
-
-
Idaho
-
Meridian, Idaho, Stany Zjednoczone, 83642
- Jeszcze nie rekrutacja
- St. Luke's Clinic - Idaho Cardiology Associates
-
Kontakt:
- Brian Nolan
- Numer telefonu: 208-322-1680
- E-mail: bnolan@slhs.org
-
-
Illinois
-
Springfield, Illinois, Stany Zjednoczone, 62781
- Jeszcze nie rekrutacja
- Southern Illinois University School of Medicine
-
Kontakt:
- Abdul Hafiz, MD
- Numer telefonu: 217-545-8000
- E-mail: ahafiz96@siumed.edu
-
-
Kansas
-
Overland Park, Kansas, Stany Zjednoczone, 66211-1215
- Rekrutacyjny
- Midwest Heart & Vascular Specialists, LLC
-
Kontakt:
- Stephen Bloom, MD
- Numer telefonu: 913-253-3000
- E-mail: sbloom@kc.rr.com
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63110-1032
- Rekrutacyjny
- WU School of Medicine - (CAM) - Heart and Vascular Center
-
Kontakt:
- Farhan Katchi, MD
- Numer telefonu: 314-362-1291
- E-mail: katchif@wustl.edu
-
-
North Carolina
-
Raleigh, North Carolina, Stany Zjednoczone, 27607
- Jeszcze nie rekrutacja
- NC Heart and Vascular Research, LLC
-
Kontakt:
- Mohit Pasi
- Numer telefonu: 919-784-2300
- E-mail: mohit.pasi2@unchealth.unc.edu
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27104-3520
- Jeszcze nie rekrutacja
- Javara Inc. - Wake Forest University Health Sciences
-
Kontakt:
- Michael Shapiro, MD
- Numer telefonu: 336-713-7251
- E-mail: owen.spitz@javararesearch.com
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- Jeszcze nie rekrutacja
- The Christ Hospital
-
Kontakt:
- Mark Berlacher, MD
- Numer telefonu: 513-585-1777
- E-mail: Mark.Berlacher@thechristhospital.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73135
- Jeszcze nie rekrutacja
- South Oklahoma Heart Research, LLC
-
Kontakt:
- Naeem Tahirkheli
- Numer telefonu: 405-628-6865
- E-mail: ntahirkheli@okheart.com
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Stany Zjednoczone, 17011
- Rekrutacyjny
- Capital Area Research, LLC - Camp Hill
-
Kontakt:
- Venkatesh Nadar, MD
- Numer telefonu: 717-695-8722
- E-mail: VNadar@care-research.com
-
-
Texas
-
Amarillo, Texas, Stany Zjednoczone, 79106
- Rekrutacyjny
- PharmaTex Research, LLC
-
Kontakt:
- David Brabham
- Numer telefonu: 806-355-2581
- E-mail: dgbrabham@hotmail.com
-
Carrollton, Texas, Stany Zjednoczone, 75010
- Jeszcze nie rekrutacja
- Pulse Care Heart and Vascular
-
Kontakt:
- Kiran Kumar Mangalpally
- Numer telefonu: 214-407-8640
- E-mail: trials@stryderesearch.com
-
Tomball, Texas, Stany Zjednoczone, 77375
- Jeszcze nie rekrutacja
- DM Clinical Research - Dallas
-
Kontakt:
- Mustafa Mandviwala
- Numer telefonu: 346-550-9559
- E-mail: drmandviwala.ns@dmclinical.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
- Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
- Participants must satisfy either of the following criteria:
1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
-
A history of Type 2 diabetes requiring treatment with medication,
-
Aged > 55 years (women) or > 50 years (men),
-
2 or more of the following atherosclerosis risk factors:
-
Current cigarette smoker
-
Hypertension
-
Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
5. Female participants must be non-pregnant and non-lactating
6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.
-
Exclusion Criteria:
- Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Previously received YN001.
- Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
- Contraindication for CCTA
- 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
- Acute MI that occurred within 4 weeks prior to randomization.
- PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
- Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
- Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
- Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
- New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
- Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
- History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
- History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
- Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
- Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
- Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
- Presence of any type of autoimmune disease.
- Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
- Life expectancy is less than 1 year.
- Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
- Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
- LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
- Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
- Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
- Untreated or inadequately treated hypothyroidism.
- Poorly controlled Type 2 diabetes mellitus.
- A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
- Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Dose 1 YN001/Placebo 40mg
Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly |
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Eksperymentalny: Dose 2 YN001/Placebo 20mg
Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly |
YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Komparator placebo: Dose 3 YN001/Placebo 0mg
Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly |
YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Relative change from baseline in coronary NCPV at Week 13
Ramy czasowe: Baseline to Week 13
|
Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA) |
Baseline to Week 13
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Ramy czasowe: From baseline to Week 13
|
Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound. |
From baseline to Week 13
|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Ramy czasowe: From baseline to Week 9
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9 |
From baseline to Week 9
|
|
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Ramy czasowe: From baseline to Week 13
|
Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound |
From baseline to Week 13
|
|
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Ramy czasowe: From baseline to Week 9 and Week 13
|
Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound |
From baseline to Week 9 and Week 13
|
|
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Ramy czasowe: From baseline to Week 13
|
Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA |
From baseline to Week 13
|
|
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Ramy czasowe: From baseline to week 13
|
Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA. |
From baseline to week 13
|
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Ramy czasowe: From baseline to week 48
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA |
From baseline to week 48
|
|
Absolute change in coronary NCPV at week 13 and week 48
Ramy czasowe: From baseline to week 13 and week 48
|
Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA |
From baseline to week 13 and week 48
|
|
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Ramy czasowe: From randomization to Week 96
|
Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina |
From randomization to Week 96
|
|
The safety profile of YN001
Ramy czasowe: From baseline to Week 13
|
Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI) |
From baseline to Week 13
|
|
Immunogenicity (ADA) analysis
Ramy czasowe: From baseline to Week 13
|
Incidence of anti-drug antibodies (ADA) formation |
From baseline to Week 13
|
|
Immunogenicity (APA) analysis
Ramy czasowe: From baseline to Week 17
|
Incidence of anti-PEG antibodies (APA) formation |
From baseline to Week 17
|
|
YN001 concentrations analysis in plasma
Ramy czasowe: From baseline to Week 13
|
Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models |
From baseline to Week 13
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Dyrektor Studium: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- YN001-203
- IND 157167 (Identyfikator rejestru: Beijing Inno Medicine Co., Ltd.)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .